<DOC>
	<DOCNO>NCT00269984</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness epoetin alfa versus placebo , inject beneath skin , treatment patient persistent anemia cause advanced cancer , normal hematocrit &lt; = 37 % . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>A Study Determine Safety Effectiveness Epoetin Alfa Versus Placebo Patients With Persistent Anemia Caused Advanced Cancer</brief_title>
	<detailed_description>Patients advance cancer frequently develop significant anemia , determine blood test measure hematocrit , normal hematocrit &lt; =37 % . Agents elevate hematocrit level patient advanced cancer may increase physical strength stamen decrease anemia , increase patient ' ability persevere chemotherapy , improve overall quality life . Epoetin alfa genetically engineer form natural hormone , erythropoietin , use treat anemia stimulate red blood cell production . This randomized , double-blind , placebo-controlled , parallel group , multicenter study determine safety effectiveness treatment epoetin alfa patient persistent anemia cause advanced cancer . Eligible patient randomly assign one two treatment group : epoetin alfa 100 unit per kilogram comparable volume placebo , give injection beneath skin . Patients give study medication 3 time weekly 8 week patient 's hematocrit reach 38 % 40 % . The 8 week decrease 4 week , Week 4 , patient 's hematocrit decrease 15 % start study . At end double-blind part study , patient achieve hematocrit level 38 40 % , whose hematocrit decrease &gt; =15 % start study Week 4 , allow enroll open-label part study additional 6 month receive epoetin alfa dose adjust maintain hematocrit level 38 % 40 % . Within 5 7 day document patient 's hematocrit reach 38 % 40 % , epoetin alfa give weekly injection beneath skin maintain hematocrit 38 % 40 % remain time study . Patients see healthcare professional weekly physician monthly . Safety evaluation include change laboratory test , vital sign , physical examination , electrocardiogram , incidence adverse event start study end double-blind part study end open-label part study . Effectiveness assess blood transfusion requirement change hemoglobin , hematocrit , immature red blood cell count start study end study , well physician 's global evaluation quality life assessment end double-blind part study end open-label part study . The study hypothesis epoetin alfa well tolerated effective placebo stimulate adequate production red blood cell patient anemic result advance cancer . Double-blind : Epoetin alfa 100 units/kilogram ( U/kg ) placebo injected skin ; give 3 time weekly 8 week hematocrit reach 38 % -40 % . Open-label : Epoetin alfa 100 150 U/kg high dose inject skin schedule maintain hematocrit 38 % -40 % .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients advance cancer ( except rapid onset severe leukemia malignancy bone marrow spleen ) resistant treatment cure chemotherapy establish effective chemotherapy persistent anemia determine low hematocrit &lt; =37 % negative direct Coombs ' test ( blood test use detect protein especially certain antibody produce abnormally cancer cell surface red blood cell ) Performance score 0 , 1 , 2 , 3 ( patient ' ability perform daily activity , score range 0 [ fully active , disease restriction ] 3 [ capable limited selfcare , confine bed chair 50 % waking hour ] ) life expectancy least 3 month chemotherapy decrease cell radiation therapy within 1 month start study Patients history primary blood disease sign symptom significant disease/dysfunction cause underlying cancer iron , folate , vitamin B12 deficiency , sign symptom suggestive autoimmune disease cause blood break release ironcontaining pigment significant bleed stomach and/or intestine , uncontrolled high blood pressure , history seizure , sudden onset severe illness within 7 day start study receive androgen therapy within 2 month start study use medication know affect hematocrit within 1 month start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Blood transfusion</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Epogen</keyword>
	<keyword>Cancer</keyword>
</DOC>